Drug Trial Radar · NCT00433966
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Dec 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,602
Actual
Start
Mar 2005
Primary completion
Jun 2008
Study completion Nov 2010
Sponsor
- Lead sponsor
- Cardiovascular Research Foundation, New YorkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boston Scientific Corporation; The Medicines Company
- First posted
- Feb 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strategy. 2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™ stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.
Conditions
- Myocardial Infarction
Interventions
BivalirudinDrug
Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
Unfractionated heparinDrug
60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
Bare metal stentDevice
Uncoated bare metal stent
Paclitaxel-eluting stentDevice
slow rate-release paclitaxel-eluting stent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding EventsTime frame: 30 Days
- Stent Arm - Ischemic Target Lesion RevascularizationTime frame: 1 year
- Stent Arm - Death, Reinfarction, Stroke, or Stent ThrombosisTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LeBauer CV Research Foundation
Greensboro, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.